Celastrol inhibits proliferation and induces chemosensitization through down-regulation of NF-κB and STAT3 regulated gene products in multiple myeloma cells

British Journal of Pharmacology

Volumn 164, Issue 5, 2011, Pages 1506-1521

  Kannaiyan, Radhamani ^a   Hay, Hui Sin ^b   Rajendran, Peramaiyan ^a   Li, Feng ^a   Shanmugam, Muthu K ^a   Vali, Shireen ^c,d   Abbasi, Taher ^c,d   Kapoor, Shweta ^d   Sharma, Ashish ^d   Kumar, Alan Prem ^a   Chng, Wee Joo ^b,e   Sethi, Gautam ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c CELLWORKS GROUP INC   (United States)

^d Cellworks Research India Pvt Ltd   (India)

^e NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

Author keywords

celastrol; multiple myeloma; NF B; STAT3

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; CASPASE 3; CELASTROL; CYCLIN D1; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; STAT3 PROTEIN; SURVIVIN; SYNAPTOTAGMIN I; THALIDOMIDE; X LINKED INHIBITOR OF APOPTOSIS;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIOACCUMULATION; CANCER RESISTANCE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CHEMOSENSITIZATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENE REPRESSION; HUMAN; HUMAN CELL; MONOTHERAPY; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BLOTTING, WESTERN; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HUMANS; IMMUNOHISTOCHEMISTRY; MODELS, BIOLOGICAL; MULTIPLE MYELOMA; NF-KAPPA B; REAL-TIME POLYMERASE CHAIN REACTION; STAT3 TRANSCRIPTION FACTOR; TRITERPENES;

EID: 80054024030     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01449.x     Document Type: Article

References (57)

1. Aggarwal BB, Sethi G, Ahn KS, Sandur SK, Pandey MK, Kunnumakkara AB, et al,. (2006). Targeting signal-transducer-and-activator-of-transcription-3 for prevention and therapy of cancer: modern target but ancient solution. Ann N Y Acad Sci 1091: 151-169. (Pubitemid 47092233)
2. Aggarwal BB, Vijayalekshmi RV, Sung B, (2009). Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin Cancer Res 15: 425-430.
3. Bhardwaj A, Sethi G, Vadhan-Raj S, Bueso-Ramos C, Takada Y, Gaur U, et al,. (2007). Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-κB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. Blood 109: 2293-2302. (Pubitemid 46425866)
4. Bharti AC, Donato N, Singh S, Aggarwal BB, (2003). Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood 101: 1053-1062. (Pubitemid 36139379)
5. Campbell GS, Yu CL, Jove R, Carter-Su C, (1997). Constitutive activation of JAK1 in Src-transformed cells. J Biol Chem 272: 2591-2594. (Pubitemid 27053296)
6. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, et al,. (1999). Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 10: 105-115. (Pubitemid 29077388)
7. Cavo M, Baccarani M, (2006). The changing landscape of myeloma therapy. N Engl J Med 354: 1076-1078. (Pubitemid 43357812)
8. Cirstea D, Hideshima T, Rodig S, Santo L, Pozzi S, Vallet S, et al,. (2010). Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma. Mol Cancer Ther 9: 963-975.
9. Conticello C, Giuffrida R, Adamo L, Anastasi G, Martinetti D, Salomone E, et al,. (2011). NF-kappaB localization in multiple myeloma plasma cells and mesenchymal cells. Leuk Res 35: 52-60.
10. Dai Y, DeSano JT, Meng Y, Ji Q, Ljungman M, Lawrence TS, et al,. (2009). Celastrol potentiates radiotherapy by impairment of DNA damage processing in human prostate cancer. Int J Radiat Oncol Biol Physics 74: 1217-1225.
11. Digicaylioglu M, Lipton SA, (2001). Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades. Nature 412: 641-647. (Pubitemid 32772276)
12. Feinman R, Koury J, Thames M, Barlogie B, Epstein J, Siegel DS, (1999). Role of NF-κB in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by bcl-2. Blood 93: 3044-3052. (Pubitemid 29200797)
13. Garcia R, Bowman TL, Niu G, Yu H, Minton S, Muro-Cacho CA, et al,. (2001). Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 20: 2499-2513. (Pubitemid 32531347)
14. Glasmacher A, Hahn C, Hoffmann F, Naumann R, Goldschmidt H, von Lilienfeld-Toal M, et al,. (2006). A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br J Haematol 132: 584-593. (Pubitemid 43381591)
15. Hideshima T, Chauhan D, Shima Y, Raje N, Davies FE, Tai YT, et al,. (2000). Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 96: 2943-2950.
16. Huang Y, Zhou Y, Fan Y, Zhou D, (2008). Celastrol inhibits the growth of human glioma xenografts in nude mice through suppressing VEGFR expression. Cancer Lett 264: 101-106.
17. Jagannath S, (2005). Novel agents in first-line therapy for myeloma: from the multiple myeloma research foundation. Oncology 19: 1551-1554. (Pubitemid 46511206)
18. Jagannath S, Kyle R, Palumbo A, Siegel D, Cunningham S, Berenson J, (2010). The current status and future of multiple myeloma in the clinic. Clin Lymphoma Myeloma 10: E1-E16.
19. Kannaiyan R, Shanmugam MK, Sethi G, (2010). Molecular targets of celastrol derived from Thunder of God Vine: potential role in the treatment of inflammatory disorders and cancer. Cancer Lett 303: 9-20.
20. Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K, et al,. (1988). Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 332: 83-85.
21. Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, Chng WJ, et al,. (2007). Promiscuous mutations activate the noncanonical NF-κB pathway in multiple myeloma. Cancer Cell 12: 131-144. (Pubitemid 47208626)
22. Kumar AP, Quake AL, Chang MK, Zhou T, Lim KS, Singh R, et al,. (2009). Repression of NHE1 expression by PPARgamma activation is a potential new approach for specific inhibition of the growth of tumor cells in vitro and in vivo. Cancer Res 69: 8636-8644.
23. Kumar S, Rajkumar SV, (2006). Thalidomide and lenalidomide in the treatment of multiple myeloma. Eur J Cancer 42: 1612-1622. (Pubitemid 44118763)
24. Kyle RA, Rajkumar SV, (2004). Drug therapy: multiple myeloma. N Engl J Med 351: 1860-1873 + 1921.
25. Kyle RA, Rajkumar SV, (2008). Multiple myeloma. Blood 111: 2962-2972.
26. Lee H, Herrmann A, Deng JH, Kujawski M, Niu G, Li Z, et al,. (2009). Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell 15: 283-293.
27. Li F, Sethi G, (2010). Targeting transcription factor NF-κB to overcome chemoresistance and radioresistance in cancer therapy. Biochim Biophys Acta-Rev Cancer 1805: 167-180.
28. Li F, Fernandez PP, Rajendran P, Hui KM, Sethi G, (2010). Diosgenin, a steroidal saponin, inhibits STAT3 signaling pathway leading to suppression of proliferation and chemosensitization of human hepatocellular carcinoma cells. Cancer Lett 292: 197-207.
29. Li-Weber M, (2010). Targeting apoptosis pathways in cancer by Chinese medicine. Cancer Lett [Epub ahead of print].
30. Lu Z, Jin Y, Qiu L, Lai Y, Pan J, (2010). Celastrol, a novel HSP90 inhibitor, depletes Bcr-Abl and induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation. Cancer Lett 290: 182-191.
31. Morita H, Hirasawa Y, Muto A, Yoshida T, Sekita S, Shirota O, (2008). Antimitotic quinoid triterpenes from Maytenus chuchuhuasca. Bioorg Med Chem Lett 18: 1050-1052. (Pubitemid 351187879)
32. Ni H, Ergin M, Huang Q, Qin JZ, Amin HM, Martinez RL, et al,. (2001). Analysis of expression of nuclear factor κB (NF-κB) in multiple myeloma: downregulation of NF-κB induces apoptosis. Br J Haematol 115: 279-286. (Pubitemid 34203489)
33. Pang X, Yi Z, Zhang J, Lu B, Sung B, Qu W, et al,. (2010). Celastrol suppresses angiogenesis-mediated tumor growth through inhibition of AKT/mammalian target of rapamycin pathway. Cancer Res 70: 1951-1959.
34. Paris D, Ganey NJ, Laporte V, Patel NS, Beaulieu-Abdelahad D, Bachmeier C, et al,. (2010). Reduction of β-amyloid pathology by celastrol in a transgenic mouse model of Alzheimer's disease. J Neuroinflammation 7: 1-15.
35. Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC, (2009). Multiple myeloma. Lancet 374: 324-339.
36. Renard P, Ernest I, Houbion A, Art M, Le Calvez H, Raes M, et al,. (2001). Development of a sensitive multi-well colorimetric assay for active NFkappaB. Nucleic Acids Res 29: E21.
37. Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, et al,. (2006). Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 24: 3113-3120. (Pubitemid 46638949)
38. Roy KR, Reddy GV, Maitreyi L, Agarwal S, Achari C, Vali S, et al,. (2010). Celecoxib inhibits MDR1 expression through COX-2-dependent mechanism in human hepatocellular carcinoma (HepG2) cell line. Cancer Chemother Pharmacol 65: 903-911.
39. Salminen A, Lehtonen M, Paimela T, Kaarniranta K, (2010). Celastrol: molecular targets of Thunder God Vine. Biochem Biophys Res Commun 394: 439-442.
40. Schreiner SJ, Schiavone AP, Smithgall TE, (2002). Activation of STAT3 by the Src family kinase Hck requires a functional SH3 domain. J Biol Chem 277: 45680-45687. (Pubitemid 36159180)
41. Sethi G, Tergaonkar V, (2009). Potential pharmacological control of the NF-κB pathway. Trends Pharmacol Sci 30: 313-321.
42. Sethi G, Ahn KS, Pandey MK, Aggarwal BB, (2007a). Celastrol, a novel triterpene, potentiates TNF-induced apoptosis and suppresses invasion of tumor cells by inhibiting NF-kappaB-regulated gene products and TAK1-mediated NF-kappaB activation. Blood 109: 2727-2735. (Pubitemid 46482064)
43. Sethi G, Kwang SA, Pandey MK, Aggarwal BB, (2007b). Celastrol, a novel triterpene, potentiates TNF-induced apoptosis and suppresses invasion of tumor cells by inhibiting NF-κB-regulated gene products and TAK1-mediated NF-κB activation. Blood 109: 2727-2735. (Pubitemid 46482064)
44. Sethi G, Ahn KS, Sung B, Kunnumakkara AB, Chaturvedi MM, Aggarwal BB, (2008). SH-5, an AKT inhibitor potentiates apoptosis and inhibits invasion through the suppression of anti-apoptotic, proliferative and metastatic gene products regulated by IkappaBalpha kinase activation. Biochem Pharmacol 76: 1404-1416.
45. Shah JJ, Orlowski RZ, (2009). Proteasome inhibitors in the treatment of multiple myeloma. Leukemia 23: 1964-1979.
46. Sizemore N, Leung S, Stark GR, (1999). Activation of phosphatidylinositol 3-kinase in response to interleukin-1 leads to phosphorylation and activation of the NF-kappaB p65/RelA subunit. Mol Cell Biol 19: 4798-4805. (Pubitemid 29289518)
47. Sung B, Kunnumakkara AB, Sethi G, Anand P, Guha S, Aggarwal BB, (2009). Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model. Mol Cancer Ther 8: 959-970.
48. Sung B, Park B, Yadav VR, Aggarwal BB, (2010). Celastrol, a triterpene, enhances TRAIL-induced apoptosis through the down-regulation of cell survival proteins and up-regulation of death receptors. J Biol Chem 285: 11498-11507.
49. Tan SM, Li F, Rajendran P, Kumar AP, Hui KM, Sethi G, (2010). Identification of beta-escin as a novel inhibitor of signal transducer and activator of transcription 3/Janus-activated kinase 2 signaling pathway that suppresses proliferation and induces apoptosis in human hepatocellular carcinoma cells. J Pharmacol Exp Ther 334: 285-293.
50. Tu Y, Renner S, Xu FH, Fleishman A, Taylor J, Weisz J, et al,. (1998). BCL-X expression in multiple myeloma: possible indicator of chemoresistance. Cancer Res 58: 256-262. (Pubitemid 28047064)
51. Vali S, Pallavi R, Kapoor S, Tatu U, (2010). Virtual prototyping study shows increased ATPase activity of Hsp90 to be the key determinant of cancer phenotype. Syst Synth Biol 4: 25-33.
52. Yadav VR, Sung B, Prasad S, Kannappan R, Cho SG, Liu M, et al,. (2010). Celastrol suppresses invasion of colon and pancreatic cancer cells through the downregulation of expression of CXCR4 chemokine receptor. J Mol Med 88: 1243-1253.
53. Yamaguchi H, Wang HG, (2001). The protein kinase PKB/Akt regulates cell survival and apoptosis by inhibiting Bax conformational change. Oncogene 20: 7779-7786. (Pubitemid 33121951)
54. Yu X, Tao W, Jiang F, Li C, Lin J, Liu C, (2010). Celastrol attenuates hypertension-induced inflammation and oxidative stress in vascular smooth muscle cells via induction of heme oxygenase-1. Am J Hypertens 23: 895-903.
55. Yue P, Turkson J, (2009). Targeting STAT3 in cancer: how successful are we? Expert Opin Investig Drugs 18: 45-56.
56. Zhang D, Xu L, Cao F, Wei T, Yang C, Uzan G, et al,. (2010). Celastrol regulates multiple nuclear transcription factors belonging to HSP90's clients in a dose- and cell type-dependent way. Cell Stress Chaperones 15: 939-946.
57. Zhu H, Ding WJ, Wu R, Weng QJ, Lou JS, Jin RJ, et al,. (2010). Synergistic anti-cancer activity by the combination of TRAIL/APO-2L and celastrol. Cancer Invest 28: 23-32.